Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.
Am J Emerg Med
; 61: 235.e5-235.e6, 2022 11.
Article
in English
| MEDLINE | ID: covidwho-2075854
ABSTRACT
The return of COVID-19 symptoms after Nirmatrelvir/Ritonavir (Nm/R) treatment is being increasingly reported. Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention. Here we present a male veteran reporting rebound symptoms who was found to be hypoxic with pulmonary emboli. Our case highlights the need to evaluate known complications of SARS-CoV-2 including venous thromboembolism in patients reporting recurring symptoms. Further, cases of severe rebound phenomenon should continue to be reported by clinicians to better appreciate the use of the Nm/R during the Omicron wave and among vaccinated persons.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Embolism
/
COVID-19
Type of study:
Case report
/
Experimental Studies
Topics:
Vaccines
/
Variants
Limits:
Humans
/
Male
Language:
English
Journal:
Am J Emerg Med
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS